Amgen (AMGN) vs Biogen (BIIB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Biogen (BIIB) has outperformed Amgen (AMGN) over the past year, gaining 44.7% versus a gain of 38.3%. Over five years, AMGN leads with a +96.0% price change compared with -22.3% for BIIB. Amgen is the larger company by market cap ($225.37 billion vs $33.28 billion), about 6.8 times the size.
On valuation, Biogen trades at a lower forward P/E (13.6x vs 17.0x for Amgen). Amgen pays a dividend yielding 2.35%, while Biogen does not currently pay one. Amgen converts more of its revenue into profit, with a net margin of 21.0% versus 13.1%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AMGN | BIIB |
|---|---|---|
| Share price | $416.87 | $225.26 |
| Market cap | $225.37B | $33.28B |
| 1-day change | +2.31% | +3.13% |
| YTD return | +24.48% | +24.12% |
| 1-year return | +38.29% | +44.68% |
| 5-year return | +96.04% | -22.32% |
| P/E ratio (TTM) | 25.89 | 40.01 |
| Forward P/E | 17.03 | 13.62 |
| EPS (TTM) | $16.10 | $5.63 |
| Dividend yield | 2.35% | 0.00% |
| Annual dividend | $9.80 | $0.00 |
| Revenue (latest FY) | $36.75B | $9.89B |
| Revenue growth (YoY) | +9.95% | +2.22% |
| Net income (latest FY) | $7.71B | $1.29B |
| Gross margin | 67.25% | 75.69% |
| Operating margin | 24.71% | — |
| Net margin | 20.98% | 13.07% |
| 52-week high | $447.03 | $230.49 |
| 52-week low | $288.00 | $138.00 |
| Distance from 52-week high | -6.75% | -2.27% |
| Analyst consensus | hold | buy |
| Avg. price target upside | -6.09% | +5.74% |
| Average volume | 2.74M | 1.06M |
| Shares outstanding | 540.63M | 147.75M |
| Employees | 31,500 | 7,500 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Amgen is about 6.8 times larger than Biogen by market value ($225.37B vs $33.28B).
- Biogen trades at a higher earnings multiple (40.0x vs 25.9x trailing P/E).
- Amgen offers a meaningfully higher dividend yield (2.35% vs 0.00%).
- Amgen is more profitable, keeping 21.0 cents of every revenue dollar as net income versus 13.1 cents for Biogen.
- Amgen grew revenue faster in its latest fiscal year (+9.95% vs +2.22%).
About Amgen
AMGN stock →Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 31,500 employees
About Biogen
BIIB stock →Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 7,500 employees
AMGN vs BIIB FAQ
Which is bigger, Amgen or Biogen?
Amgen (AMGN) is larger, with a market capitalization of $225.37B compared with $33.28B for Biogen (BIIB).
Which stock has performed better over the past year, AMGN or BIIB?
BIIB returned +44.68% over the past 12 months, compared with +38.29% for AMGN (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, AMGN or BIIB?
AMGN has the lower trailing P/E at 25.9, versus 40.0 for BIIB. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Amgen or Biogen?
Amgen pays a dividend yielding 2.35%, while Biogen does not currently pay a regular dividend.
Are Amgen and Biogen in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.